100
Participants
Start Date
December 3, 2024
Primary Completion Date
February 6, 2025
Study Completion Date
March 10, 2025
3% Hypertonic Saline
In this arm of the study, participants will receive nebulized 3% hypertonic saline as the primary treatment for bronchiolitis. The administration of hypertonic saline is aimed at reducing airway edema and improving mucociliary clearance in infants experiencing respiratory distress due to bronchiolitis.
Intervention: Salbutamol (Ventolin)
In this arm of the study, participants will receive nebulized Salbutamol, a bronchodilator commonly used in the management of bronchospasm associated with respiratory conditions, including bronchiolitis. The objective is to evaluate the effectiveness of Salbutamol in comparison to 3% hypertonic saline in improving the clinical outcomes of infants with bronchiolitis.
University of Health Sciences Lahore
OTHER